Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (NCT00977574)
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
🩺 Plain-English Summary (8th-Grade Level)
This randomized phase II trial studies paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab to see how well they work in treating patients with stage III, stage IV, or recurrent endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known which treatment regimen is most effective in treating patients with endometrial cancer.
Who can join: Review the eligibility criteria below.
Location: Saint Joseph's Hospital and Medical Center — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (230 Sites)
Showing the first 25 of 230 sites.
- Saint Joseph's Hospital and Medical Center — Phoenix, Arizona
- Mayo Clinic in Arizona — Scottsdale, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- John Muir Medical Center-Concord — Concord, California
- UC San Diego Moores Cancer Center — La Jolla, California
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
- Palo Alto Medical Foundation-Gynecologic Oncology — Mountain View, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
- San Diego VA Medical Center — San Diego, California
- UCSF Medical Center-Mount Zion — San Francisco, California
- John Muir Medical Center-Walnut Creek — Walnut Creek, California
- UCHealth University of Colorado Hospital — Aurora, Colorado
- Rocky Mountain Gynecologic Oncology PC — Englewood, Colorado
- Hartford Hospital — Hartford, Connecticut
- Smilow Cancer Hospital Care Center at Saint Francis — Hartford, Connecticut
- The Hospital of Central Connecticut — New Britain, Connecticut
- Yale University — New Haven, Connecticut
- Beebe Medical Center — Lewes, Delaware
- Christiana Care Health System-Christiana Hospital — Newark, Delaware
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Morton Plant Hospital — Clearwater, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
- AdventHealth Orlando — Orlando, Florida
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Endometrial Adenocarcinoma
- Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone — Birmingham, Alabama
- Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment — Basking Ridge, New Jersey
- A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma — Mobile, Alabama
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma — Birmingham, Alabama
Explore by condition: All Endometrial Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.